Previous research suggests that P2X7 receptor antagonists could improve behavioral symptoms, microglial activation, and neuroendocrine abnormalities in individuals with depression, thus providing new targets for novel treatments for depression [59]. Here, P2RX7 is linked to depressive disorder.